First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
نویسندگان
چکیده
The European Respiratory Journal has recently discussed delamanid and bedaquiline and their use in difficult-to-treat cases affected by multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant (XDR-TB) [1–4]. The use of delamanid or bedaquiline is particularly important when four active drugs cannot be identified and included in a regimen, as per World Health Organization (WHO) guidelines [1–6]. Recently a debate has been initiated around the report of a severe, almost untreatable, XDR-TB case who could not access both new drugs simultaneously [7–10] due to concerns about possible additive toxicity (cardiotoxicity), as well as the lack of evidence and specific guidance on their combined use [10–13].
منابع مشابه
Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/ medicinedocs/documents/s21535en/s21535en.pdf 6 Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186. 7 Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline a...
متن کاملCombined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline use...
متن کاملDelamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
متن کامل
Profile of delamanid for the treatment of multidrug-resistant tuberculosis
New approaches to the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) are badly needed. Not only is the success rate of current treatment regimens suboptimal but existing regimens require multiple drugs and lengthy courses and may lead to significant toxicities. The treatment landscape is beginning to shift, however, with the recent approvals of the new TB drug...
متن کاملBedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this therapy is justified for patients with limited options.
متن کامل